Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $25.19 Consensus PT from Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $25.1875.

A number of research analysts recently weighed in on ROIV shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Roivant Sciences in a research report on Thursday, January 22nd. Leerink Partners upped their price objective on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Guggenheim reissued a “buy” rating and issued a $28.00 target price on shares of Roivant Sciences in a research note on Thursday, December 18th. Citigroup lifted their price objective on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Finally, The Goldman Sachs Group upped their target price on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 15th.

Insider Transactions at Roivant Sciences

In other news, CFO Richard Pulik sold 406,731 shares of the stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $22.43, for a total value of $9,122,976.33. Following the transaction, the chief financial officer directly owned 239,413 shares of the company’s stock, valued at $5,370,033.59. This represents a 62.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mayukh Sukhatme sold 1,018,995 shares of the firm’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $21.71, for a total transaction of $22,122,381.45. Following the sale, the insider owned 20,267,429 shares of the company’s stock, valued at approximately $440,005,883.59. This represents a 4.79% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 12,332,392 shares of company stock valued at $266,393,645. Company insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors have recently made changes to their positions in ROIV. Jones Financial Companies Lllp increased its position in Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after acquiring an additional 1,148 shares during the period. Allworth Financial LP grew its position in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares during the last quarter. Bessemer Group Inc. boosted its position in Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after buying an additional 543 shares in the last quarter. CWM LLC raised its position in Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after purchasing an additional 920 shares during the last quarter. Finally, Osaic Holdings Inc. increased its position in Roivant Sciences by 204.2% in the 2nd quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock valued at $65,000 after acquiring an additional 3,882 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock opened at $21.62 on Friday. The firm has a market cap of $15.04 billion, a PE ratio of -38.61 and a beta of 1.22. The business’s 50 day simple moving average is $21.89 and its 200 day simple moving average is $17.47. Roivant Sciences has a 52-week low of $8.73 and a 52-week high of $23.91.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.